![FDA Rejects Rocket Pharma's Gene Therapy, Stock Falls](/content/images/size/w600/2024/06/eb416762-c9f8-4371-b94b-def3ff645a4f.png)
Health
FDA Rejects Rocket Pharma's Gene Therapy, Stock Falls
The US Food and Drug Administration (FDA) has declined to approve Rocket Pharmaceuticals' gene therapy, Kresladi, intended for treating Leukocyte Adhesion Deficiency-I (LAD-I), a rare and severe pediatric disorder that causes the immune system to malfunction. The FDA requested additional information regarding certain processes related to the gene therapy